Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 14/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.52 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.52 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7689316 | 0.99 | EGLN1 (0.98) | EGLN1PKMALDH1A1RCE1NPC1 | |
| SCHEMBL19347369 | 0.85 | EGLN1 (0.73) | EGLN1PKMRCE1NPC1CASP3 | |
| SCHEMBL2201326 | 0.84 | EGLN1 (1.00) | EGLN1ALDH1A1NPC1CASP3RAB9A | |
| SCHEMBL7685082 | 0.84 | EGLN1 (0.78) | EGLN1ALDH1A1NPC1CASP3RAB9A | |
| SCHEMBL19347296 | 0.83 | EGLN1 (0.71) | EGLN1PKMALDH1A1 | |
| SCHEMBL19347291 | 0.83 | EGLN1 (0.71) | EGLN1PKMALDH1A1 | |
| SCHEMBL7689924 | 0.82 | EGLN1 (0.76) | EGLN1ALDH1A1NPC1CASP3RAB9A | |
| Hydrochloric Acid SCHEMBL7692185 | 0.82 | EGLN1 (0.76) | EGLN1ALDH1A1RCE1NPC1CASP3 | |
| SCHEMBL23627651 | 0.82 | EGLN1 (0.69) | EGLN1PKMRCE1NPC1CASP3 | |
| SCHEMBL7686835 | 0.82 | EGLN1 (0.69) | EGLN1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| WO-2017156489-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2017-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205292-A1 | INHIBITORS OF CREB-CBP INTERACTION FOR TREATMENT OF LEUKEMIA | CREBBP, CREB1, EP300 | EGLN1 237/4885PKM 3706/4885ALDH1A1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.